Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Apr 18, 2008

Critical Therapeutics : Phase I Clinical Trial of the R(+) Isomer of Zileuton

April 8, 2008- Critical Therapeutics, Inc. (Nasdaq: CRTX) announced the results of its Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO CR(TM) (zileuton) extended-release tablets... Critical Therapeutics' Press Release -